Actuellement les prothèses d’épaules dites inversées sont préconisées dans le cas de coiffe des rotateurs endommagée. Ces prothèses assurent la stabilité de l’articulation mais limitent la mobilité articulaire, notamment en élévation du bras. Pour pallier cette déficience, Statera Medical propose un design de prothèse innovant avec un degré de liberté additionnel. En collaboration avec le laboratoire de simulation et modélisation du mouvement, cette nouvelle prothèse sera testée puis optimisée par des simulations musculosquelettiques.
Different autoimmune diseases often have similar mechanisms that trigger and drive the pathology. Therefore, it’s logical that having one autoimmune disorder increases the risk of acquiring another one. At the same time, autoimmune disease cooccurrence is rare. Our research found that type 1 diabetes (T1D) and multiple sclerosis (MS) share common mechanisms. We pinpointed the protein, called NLRX1, that protects against both autoimmune diseases. This protein belongs to the class of pattern recognition receptors that we use to detect pathogens.
With the imminent emergence of personalized medicine and the availability of costly targeted drugs comes the crucial allocation of ressources within the halthcare systems. Determining which treatment options should be funded has become an increasingly difficult task. Decision-makers are relying heavily on pharmacoeconomic (PE) evalutions to decide which of them will be most effective and safe—but also, which will most improve the quality of life of patients and which will be most valued by society.
Myopathies are a group of muscle diseases that are caused by over 150 genes variants, leading to muscle weakness and/or wasting. In addition to the emotional, physical and social impact on the patients and their families, the medical expenditure for the patients affected by myopathies is substantial, about $7.2 billion in Canada, which makes it the 4th diagnostic category with the largest total cost for the healthcare system.
Le diabète de type 2 (DT2) frappe plusieurs communautés autochtones au Québec comme ailleurs dans le monde. Cette maladie non-transmissible peut être bien gérée par l’adoption de saines habitudes de vie. Par contre, les programmes habituels de saines habitudes de vie offerts aux autochtones ne tiennent pas compte de leur contexte culturel. Le projet vise donc à proposer une intervention en saines habitudes de vie centrée sur l’alimentation traditionnelle, la médecine traditionnelle et l’activité physique culturelle.
The aim of the project is to evaluate the strain that COVID-19 has put on the Canadian public healthcare system and access to treatment. The government has primarily focused on containing and overcoming the pandemic. Most research and development as well as clinical trials (unrelated to COVID-19) were put on hold to ensure that all available resources were dedicated to the development and testing of vaccines. The effect of COVID-19 on the public healthcare system and access to treatment remains unknow.
Social medias data bases are important for continuous and automated Adverse Drug Reactions (ADRs) surveillance. Predicting ADRs can reduce the related mortality. A systematic review of the medical scientific literature is required for tracking and identifying the risk/benefit ratio of drugs and safety issues.
The implementation of means of standardizing patient’s language used in social media such as Twitter will improve the precision of ADR detection and continuous surveillance at post-marketing phase of drugs (off-label drug uses included).
Retinopathy of prematurity (ROP) is the leading cause of blindness in premature neonates. ROP is associated with inflammation largely mediated trough interleukin (IL-1), which triggers an initial critical phase of ocular vascular degeneration. ROP is also an excellent model of ischemic retinopathies in general. The formation of new blood vessels after tissue ischemia is not only restricted to local endothelial cell proliferation, but lately shown to involve endothelial progenitor cells (EPCs) capable of forming a neovascular network on their own.
La presente recherche traite de l'evaluation des risques faisant obstacle a la liberte d'exploitation (FTO) d'un produit biologique, tel que levaccin XX d'influenza developpe par Medicago®. Elle correspond a la derniere etape du systeme de controle P.I. et a, notamment, pour objet d'identifier de nouveaux risques, mais egalement de mettre a jour taus les risques prealablement identifies. Elle vise egalement a evaluer et caracteriser les couvertures P.I. entourant le vaccin (marques de commerce, brevets, secrets commerciaux, licences, etc.) sur les juridictions pertinentes.
Actuellement, les médicaments sous ordonnance sont testés rigoureusement durant plusieurs années, d’abord sur des cellules animales et humaines, puis sur des animaux et finalement chez des humains avant de pouvoir être approuvés par une agence règlementaire telle que Santé Canada. Pour certains médicaments, les études cliniques chez les humains peuvent être difficiles ou même impossibles à effectuer.
